Eyal Attar
Chief Tech/Sci/R&D Officer en VOR BIOPHARMA INC. .
Fortuna: 267 569 $ al 31/03/2024
Perfil
Eyal C.
Attar is currently the Chief Medical Officer at Vor Biopharma, Inc. Prior to this, he worked as the Senior Medical Director at Agios Pharmaceuticals, Inc. from 2016 to 2019.
He also served as the Chief Medical Officer & Senior Vice President at Aprea Therapeutics, Inc. Dr. Attar's education includes a doctorate degree from UNC School of Medicine.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
VOR BIOPHARMA, INC.
0.17% | 06/02/2024 | 112 853 ( 0.17% ) | 267 462 $ | 31/03/2024 |
APREA THERAPEUTICS, INC.
0.00% | 26/06/2023 | 16 ( 0.00% ) | 107 $ | 31/03/2024 |
Cargos activos de Eyal Attar
| Empresas | Cargo | Inicio |
|---|---|---|
| VOR BIOPHARMA INC. | Chief Tech/Sci/R&D Officer | 12/10/2022 |
Antiguos cargos conocidos de Eyal Attar.
| Empresas | Cargo | Fin |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2019 |
| Harvard Medical School | Corporate Officer/Principal | - |
| APREA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Formación de Eyal Attar.
| UNC School of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| VOR BIOPHARMA INC. | Health Technology |
| APREA THERAPEUTICS, INC. | Health Technology |
- Bolsa de valores
- Insiders
- Eyal Attar
